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ABSTRACT
Endometrial cancer (EC) is a hormone-dependent cancer that currently
represents the most frequent malignancy of the female reproductive tract.
The involvement of steroid hormones in its etiology and progression has
been reported. The possibility that even gonadotropins (GT) could play a
role in the genesis and establishment of EC is supported by the fact that
specific receptors for the GT luteinizing hormone/human chorionic GT
(LH/hCG) have been detected in a high percentage of ECs, and their
expression is apparently related to the cancer grading. However, the
precise mechanisms by which GTs might exert their effect on EC is still
obscure. The aim of this study was to determine the effects of LH/hCG on
the invasion potential of EC cell lines and primary human EC cells.
Human recombinant (hr) LH (and hCG) induced a significant increase in
cell invasiveness through Matrigel-coated porous membranes in an EC
human cell line Hec1A, which expresses the LH/hCG receptor. This effect
turned out to depend on hrLH binding to its specific receptors and to the
subsequent activation of protein kinase A (PKA). Moreover the hrLH-
induced increase in Hec1A invasiveness relied upon a PKA-dependent
functional activation of 1 integrin receptors, as well as the subsequent
induction of matrix metalloproteinase-2 secretion in its active form. The
same mechanisms were also found to be operative in primary EC cells. In
fact, a significant percentage of primary ECs expressed the LH/hCG
receptor, and hrLH addition to primary EC cells, which expressed the
specific receptors produced an increase in cell invasiveness only in those
tumor cells possessing the specific receptors. This effect was also depen-
dent on PKA activity. We conclude that LH/hCG can regulate EC cells
invasiveness, and this result provides a rationale for the use of inhibitors
of LH secretion such as GnRH analogues in the treatment of EC.
INTRODUCTION
EC3 is currently the most frequent malignancy of the female re-
productive tract, with an incidence of 22 of 100,000 and a mortality
rate of 3.2 of 100,000 in the Western countries (1). The etiology of EC
is well understood: prolonged exposure to Es without P can modulate
the mitogenic effect of E, thus contributing to the malignant transfor-
mation of endometrial surface epithelium (2, 3). The level of E and P
is well regulated by the appropriate secretion of GTs, FSH, and
LH/hCG. The median age for EC is 61 years, e.g., in the postmeno-
pausal period (4), when GTs levels are high; although EC incidence
does not increase dramatically after menopause (5), some cancers
arising in this reproductive period are often more aggressive and
apparently unlinked to E secretion (6). It is possible that these E-
independent ECs (which make up only a proportion of total EC
morbidity) might be sensitive to elevated levels of LH/hCG that occur
during postmenopausal period and that these GTs might be involved
in the natural history of at least some types of ECs. In this light, it has
been recently reported that LH/hCG regulate cell proliferation in EC
cell lines (7).
On the other hand, the correlation between GTs and several other
aspects of tumor progression is still poorly known. The process of tumor
progression includes the acquisition of malignant characteristics such as
the ability of invading surrounding tissues and the bloodstream. This
invasion eventually is critical to the establishment of metastases, which is
the major hindrance to cancer therapy. Although most mechanistic stud-
ies of tumor invasion in EC have focused on the role of E (8–10), it has
recently emerged that GTs promote neoangiogenesis both inside tumors
(11) and in the chicken chorioallantoic membrane (12).
This opens the possibility that GTs could directly regulate tumor
progression of EC by binding to specific receptors. In fact specific
LH/hCG-Rs have been detected in human EC, and their expression is
apparently related to the cancer grading (13). In particular, two
isoforms of this receptor arising from alternative splicing of the
corresponding gene are documented in EC samples (13), as well as in
neoplastic ovarian tissues (14).
The LH/hCG-R is a transmembrane glycoprotein receptor, which is
a member of the G protein-coupled receptor family (15). The ligand-
receptor binding induces the activation of signaling pathways centered
on the cAMP/PKA system as well as on PLC/inositide tris-phosphate
pathway (15, 16). It has been reported (15) that the prevalence of one
or the other signaling pathways depends on the cell type involved and
the amount of receptor expressed on the plasma membrane (17). In
endometrial cells of porcine origin, it has been recently reported (18)
that LH induces the activation of both cAMP/PKA and PLC/inositide
tris-phosphate pathways.
On the basis of these findings, we started a study aimed at deter-
mining the effects of LH/hCG system in tumor progression of EC by
analyzing the effects of such hormones on the invasion potential of
both EC cell lines and primary human EC cells. We report here that
hrLH (as well as hCG) induced a significant increase in cell invasive-
ness through Matrigel-coated porous membranes in the human EC cell
line Hec1A, which expresses the LH/hCG-R. This effect turned out to
depend on the hrLH binding to its specific receptor and on the
following activation of the cAMP/PKA signaling pathway. Moreover,
the hrLH-induced increase in Hec1A invasiveness was dependent
upon the functional activation of 1 integrin receptors and the subse-
quent induction of MMP-2 secretion. Interestingly, these mechanisms
were found to be operative in primary EC cells transferred in vitro
because hrLH addition produced an increase in cells invasiveness in
those primary EC tumors that expressed the LH/hCG-R. Here again,
this effect was dependent on PKA activity.
On the whole, data presented in this article show that LH/hCG can
regulate EC cell invasiveness, and this provides a rationale for the use
of inhibitors of LH secretion such as GnRH analogues in the treatment
of EC (19).
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MATERIALS AND METHODS
Chemicals. Matrigel Basement Membrane Matrix by Becton Dickinson
Labware (Becton Dickinson, Franklin Lakes, NJ) was used at a final concen-
tration of 250 g/ml and following the instructions from the Thin Coating
Method. hrLH: Lhadi (Lutropina ) 75 UI (3.4 g; Serono Laboratories,
Geneva, Switzerland) was used at 0.3 UI/ml (6). hCG: Profasi 5000 HP
(Serono Laboratories, Geneva, Switzerland) was used at 5000 UI/ml. The
inhibitor of PKA H89 (N-5-isoquinolinesulfonamide hydrochloride; Sigma
Chemical Company, St. Louis, MO) was used at a final concentration of
50 M. The inhibitor of PLC U73122 (Sigma Chemical Company) was used at
a final concentration of 5 M. Doses of inhibitors were chosen according to
various data reported in literature and to preliminary dose response courses.
Cell Culture. The human endometrial adenocarcinoma cell line Hec1A
(American Type Culture Collection, Manassas, VA) was routinely grown in
DMEM (Euroclone; Wetherby, West Yorkshire, United Kingdom) supple-
mented with L-glutamine (DMEM-GLUT) and 10% FCS (Euroclone, Weth-
erby; complete medium) and incubated at 37°C in 5% CO2. Primary EC
cultures were obtained from surgical specimens and prepared as reported
previously (19, 20).
Matrigel Invasion Assay. Hec1A cells, cultured as described above, were
harvested by trypsinization and resuspended in DMEM-GLUT containing 250
g/ml heat-inactivated BSA (DMEM  BSA). Cell suspension (200 l)
containing 600,000 cells was seeded into the upper well of a Boyden chamber
(NeuroProbe, Inc., Gaithersburg, MD), separated from the lower compartment
(filled with DMEM  BSA) by a porous membrane (8-m pore diameter)
previously overlaid with Matrigel (see above). All of the additions were
performed both into the upper and the lower wells. Boyden chambers were
incubated at 37°C in humidified atmosphere containing 5% CO2 in air for 24 h.
Migrated cells, which remained layering onto the lower face of the porous
membrane, were fixed with absolute methanol at 4°C overnight and stained
with Diff-Quick staining solution (Dade-Behring Holding GmbH, Liederbach,
Germany). Cells were counted on the whole migration field at 40 mag-
nification.
RT-PCR. Total RNA was extracted from either the Hec1A cells or fresh
tissue EC samples by the guanidinium/isothyocyanate method (21). cDNA was
then synthesized using 1 g of total RNA in a mix reaction with 2.5 units/l
reverse transcriptase murine leukemia virus-RT (Applied Biosystem, Foster
City, CA), 1 mM of each deoxynucleotide triphosphate, and 2.5 M random
exhamers in a 20-l final reaction volume for 30 min at 42°C and 5 min at
99°C. Ten l of each resulting cDNA template was then used to perform a
nested PCR specific for LH/hCG-R, which consists of a first amplification
using 1.25 units AmpliTaq polymerase (Applied Biosystem), 200 M of each
deoxynucleotide triphosphate, 2 mM MgCl2, and 0.15 M of the specific
primers. Ten l of the initial PCR product were used as template for a second
PCR in a reaction mix as above except that different primers, internal to the
first ones, were used. In both cases, amplification was subjected to 43 cycles
each consisting of 94°C for 1 min, 56°C for 1 min, 72°C for 1 min, and to a
72°C for 5 min cycle for final elongation. The primers used were those
described by Lin et al. (12). The omission of template in each PCR reaction
was performed as negative control.
Integrin Flow Cytometric Analysis. Hec1A cells were seeded onto Ma-
trigel-coated dishes in DMEM  BSA in the absence or in the presence of 0.3
UI/ml hrLH (see above) and incubated for 24 h as above. Cells were harvested
in PBS  EDTA (5 mM) both at time 0 and after 24 h of incubation, washed
once in PBS, and then incubated with monoclonal antibodies raised against the
1 integrin subunit (mAb TS2/16; 30 g/ml), the 3 subunit (mAb B212; 30
g/ml), and the v subunit (mAb L230; 30 g/ml) for 15 at 37°C. All of the
antibodies were kindly gifted by Dr. G. Tarone and Dr. P. Defilippi of the
University of Torino (Torino, Italy). Afterward, cells were washed and incu-
bated with an antimouse antibody labeled with FITC (Sigma Chemical Com-
pany). For the analysis, 20,000 events were collected, and the fluorescence of
samples was acquired in logarithmic scale using a FACScan flow cytometer
(Becton Dickinson, San Jose, CA) equipped with a 5-W argon-ion laser.
Adhesion Assay. Adhesion assays were performed essentially according to
Arcangeli et al. (22). Briefly, Hec1A cells were radiolabeled for 48 h of
exponential growth in complete medium containing 1 Ci/ml methyl-3H-
Fig. 1. Effect of hrLH and hCG on Hec1A invasion. Hec1A cells were inoculated into
Boyden chamber where a Matrigel-coated porous membrane (8-m pore diameter) was
inserted as described in “Materials and Methods.” At time 0, either 0.3UI/ml hrLH (a) or
5000 UI/ml hCG (b) were added to the medium; migrated cells were determined after 24 h
of incubation. Data are reported as the percentage of migrated cells as compared with
untreated cells (control) and are the means  SE of the number of experiments reported
in the figure (in bracket), each carried out in triplicate.   significantly different as
compared with “control”; P  1.26 105 (a) and P  8.65 105 (b; Student’s t test).
Fig. 2. Effect of hrLH on invasion through Matrigel of Hec1A cells and clone 1s (a)
and of Hek293 cells (b). In a, the effect of hrLH on the invasiveness of wild-type Hec1A
cells () and of the LH-R-overexpressing clone Hec1A1s () is reported. Conditions were
the same as reported in the legend to Fig. 1. Inset: RT-PCR analysis of LH/hCG-R
expression in Hec1A (Lane 1) and Hec1A clone 1s (Lane 2). St  molecular weigh
standard 100 bp (New England Biolabs, Beverly, MA). Lane 3: amplification performed
in the absence of any cDNA, to be considered as a qualitative control of the reaction.
Amplification of gapdh represents the control of RNA integrity. For experimental details,
see legend to Fig. 8. In b is reported the effect of hrLH on invasiveness of HEK 293. Data
are reported as the percentage of migrated cells as compared with untreated cells (control)
and are the means  SE of the number of experiments reported in the figure (in bracket),
each carried out in triplicate.
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thymidine (specific activity 24 Ci/mmol; Amersham Biosciences Europe
GmbH, Freiburg, Germany). After 24 h of labeling, 0.3 UI/ml hrLH were
added where needed and cells incubated for an additional 24 h. Cells were then
harvested, pelleted, and resuspended in DMEM  BSA; aliquots of cells
(1  105) were inoculated into each well of 96-well clusters (Corning B.V.,
Life Sciences, the Netherlands), previously coated with Matrigel (see before).
In the appropriate samples, blocking antibodies to FN-R (kindly gifted by Dr.
G. Tarone and Dr. P. Defilippi, University of Torino; Ref. 23) at different
dilutions were added at time 0. In any case, cells were incubated at 37°C in 5%
CO2 in air; at different times, the medium was aspirated off and adherent cells
gently rinsed twice with PBS; the cells were solubilized with 50 l of 1% SDS
in 0.1 N NaOH for 1 h. Radioactive solubilized cells were quantified by
scintillation counting and compared on a percentage basis with the radioac-
tivities of the cells inoculated in each well.
Assay of Gelatin-degrading MMPs by Zymography. The release of
MMPs in the medium of cell cultures used for the invasion assay was
determined as described by Barletta et al. (24). Briefly, concentrated superna-
tants were electrophoresed on 8% polyacrylamide gel added with porcine
gelatin (Sigma Chemical Company). After the run, the gel was incubated at
37°C for 24 h in a solution containing 50 mM Tris-HCl, 200 mM NaCl, and 5
mM CaCl2 and then stained with Coomassie blue. Samples obtained from the
medium of HT1080 cell cultures, which are known to express MMP-9 and
MMP-2 at high levels were used as controls (24).
RESULTS AND DISCUSSION
The effect of LH/hCG on cell invasiveness of Hec1A cells line, a
human EC cell line expressing the LH/hCG-R (inset in Figs. 2a and
8), was tested by analyzing the number of cells migrated through
Matrigel-covered porous membranes inserted into Boyden chambers.
As shown in Fig. 1a, hrLH increased Hec1A cell invasion through
Matrigel, almost doubling the number of cells migrated through the
membrane after 24 h of incubation. A similar effect was obtained after
addition of hCG (Fig. 1b). Interestingly, cells seeded on uncoated
porous filters displayed a moderate invading activity, which was
almost unaffected by hrLH addition (data not shown).
The effect of hrLH on Hec1A cell invasion turned out to be
dependent on LH/hCG-R expression on the plasma membrane. In fact,
the hrLH-induced increase in cell invasion through Matrigel was
10-fold in a clone of Hec1A (clone 1s; gray bars in Fig. 2a), devel-
oped in our laboratory, which expresses the LH/hCG-R at high levels
(compare Lane 2 with Lane 1 in the inset to Fig. 2a). On the other
hand, hrLH has almost no effect on the invasion of a completely
unrelated human epithelial cell line (HEK 293 cells; Fig. 2b), which
lacks the LH/hCG-R (25, 26). We also confirmed the absence of such
receptors in these cells by RT-PCR (data not shown).
Fig. 3. Effect of the PKA inhibitor H89 and the PKC inhibitor U73122 on the migration
of Hec1A cells induced by hrLH. Hec1A cells were inoculated into Boyden chamber as
described in the legend to Fig. 1 and treated with or without 0.3 UI/ml hrLH at time 0.
Where needed, 10 M H89 or 5 M U73122 were added at time 0. In any case, migrated
cells were determined after 24 h of incubation. Data are reported as the percentage of
migrated cells as compared with untreated cells (control) and are the means  SE of the
number of experiments reported in the figure (in bracket), each carried out in triplicate.
  significantly different as compared with “hrLH” (ANOVA; Bonferroni test;
P  0.044); NS  not significantly different as compared with “hrLH” (ANOVA;
Bonferroni test).
Fig. 4. Effect of hrLH on Hec1A cell adhesion to
Matrigel and modulatory effect by H 89 and anti-1
antibodies. a, effect of hrLH on cell adhesion to Ma-
trigel: cells were radiolabeled for 48 h; appropriate
samples were treated during this time for 24 h with
hrLH as reported in “Materials and Methods.” After-
ward, untreated- and hrLH-treated cells were detached
from the dish and cell suspensions inoculated into
Matrigel-coated wells (time 0) and incubated for differ-
ent times. Values are reported as adherent cells calcu-
lated as detailed in “Materials and Methods” and are the
means  SE of measurements carried out in quadrupli-
cate and refer to a typical experiment; f  hrLH-
treated cells;   control, untreated cells. b, effect of
H89 on adhesion of Hec1A cells in the presence or in
the absence of hrLH. Cells were treated as reported in
a, except that the appropriate samples were treated for
20 h with 10 M H89 at the end of the labeling time. At
the end of incubation, cells were seeded onto Matrigel-
coated wells as above. Values are reported as adherent
cells after 30 min of incubation, calculated as detailed
in “Materials and Methods” and are the means  SE of
measurements carried out in quadruplicate and refer to
a typical experiment. c, effect of anti FN-R antibodies
on cell adhesion to Matrigel in the presence of hrLH.
Experiments were performed as reported in a, except
that cells were treated with different dilution of anti-FN
receptor at the beginning of their incubation onto Ma-
trigel. Antibody dilutions were the following: 1:400;
1:200; and 1:40. Values are reported as adherent cells
after 30 min of incubation, calculated as detailed in
“Materials and Methods” and are the means  SE of
measurements carried out in quadruplicate and refer to
a typical experiment.
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The dependence of the proinvasion effect exerted by hrLH on
Hec1A cells on the signaling mechanisms induced by binding to its
specific receptor was therefore tested. It has been reported (15) that
the activation of LH/hCG-R may induce the activation of both the
cAMP/PKA and PLC/inositide tris-phosphate signaling pathways.
The involvement of both these pathways in the proinvasion effect
operated by hrLH on Hec1A cells was therefore analyzed by using
specific inhibitors (the PKA inhibitor H89 and the PLC inhibitor
U73122). As reported in Fig. 3, although the addition of H89 almost
completely inhibited the increase in cell invasiveness through Matri-
gel induced by hrLH, the PLC inhibitor U73122 had no significant
effect. It can be therefore argued that the effect of hrLH on Hec1A cell
invasiveness occurs via the signaling pathway initiated by hrLH
binding to LH/hCG-R and centered on the activation of PKA.
Because the process of tumor cell invasion is regulated both by the
engagement of adhesion receptors with proteins of the basal membrane
and of the extracellular matrix (27, 28) and by the secretion of collag-
enolytic enzymes, named MMPs (29, 30), the involvement of both these
mechanisms in the proinvasiveness effect of hrLH was tested. The
involvement of integrin receptors was tested by analyzing cell adhesion
of Hec1A cells treated or untreated with hrLH and seeded on Matrigel-
coated dishes. As shown in Fig. 4, Hec1A cells treated with hrLH adhere
more quickly to Matrigel: this effect is already evident after 30 min of
incubation, and the vast majority of cells are firmly adherent to the
substratum within 60 min of incubation, instead of after 180 min as in the
controls (Fig. 4a). Moreover, as shown in Fig. 4b, the increase in adherent
cells operated by hrLH addition after 30 min of incubation onto Matrigel
turned out to be completely abolished by cell pretreatment with H89; this
suggests that the increase in cell adhesiveness induced by hrLH relies on
the activation of the cAMP/PKA signaling pathway. Finally, because the
main integrins involved in cell adhesion to Matrigel are those containing
the 1 subunit, the involvement of this integrin subunit in the above
reported increase in cell adhesiveness to Matrigel by hrLH was tested.
Indeed, Hec1A cell adhesion to Matrigel turned out to be totally depend-
ent on 1 integrin activity as witnessed by the dose-dependent inhibitory
effect of anti-1 antibodies (anti-FN-R antibodies; Fig. 4c).
To explain these data, the possibility that hrLH induced an up-
regulation of 1 subunit on the plasma membrane was tested. The
expression of this subunit on the plasma membrane was analyzed by flow
cytometry at time 0 and after 24 h of incubation on Matrigel, both in the
absence and in the presence of hrLH. As shown in Fig. 5, although
adhesion to Matrigel induces per se an up-regulation of 1, hrLH addition
does not alter this expression pattern. Interestingly, an up-regulating
effect of Matrigel on integrin expression was evident also for two other
integrin subunits, namely 3 and v (Fig. 5, inset). Therefore, the effect
of hrLH on integrins is apparently mediated by an increase in integrin
Fig. 5. Flow cytometry analysis of 1 integrin expression in Hec1A cells. Cells were
cultured in DMEM  BSA medium on a Matrigel substrate in the absence (Control) or
in the presence (hrLH) of 0.3 UI/ml hrLH. At time 0 (T  0) and after 24 h of incubation
(T  24 h), cells were detached and incubated with anti-1 (a), anti-3, and anti-v
antibodies (insets) as reported in “Materials and Methods,” followed by an incubation with
a FITC-labeled antimouse antibody. Flow cytometry analysis was performed as reported
in “Materials and Methods.” Inset: flow cytometric analysis of 3 and v integrin
expression in Hec1A cells. Experiment was carried out as reported above. Data reported
in this figure and inset represent a typical experiment.
Fig. 6. Effect of anti-1 and anti-3 antibodies on cell invasion through Matrigel in the
presence of hrLH. a, effect of anti-1 antibodies. Cells treated as reported in the legend
to Fig. 1 were treated with different dilution of anti-1 (anti-FN receptor) antibodies at
time 0. Antibody dilutions were the following: 1/200 and 1/40. Data are reported as the
percentage of migrated cells as compared with untreated cells (control), and are the
means  SE of two separate experiments, each carried out in triplicate.   significantly
different as compared with “hrLH” (ANOVA; Bonferroni test; P  0.002);   signif-
icantly different as compared with “hrLH” (ANOVA; Bonferroni test; P  0.001); b,
effect of anti-3 antibodies. The effect of 9 g/ml anti-3 antibody was tested on Hec1A
cells and treated with hrLH as reported in the legend to Fig. 1. Data are reported as the
percentage of migrated cells as compared with untreated cells (control) and are the
means  SE of two separate experiments, each carried out in triplicate. NS  not
significantly different as compared with “hrLH” (Student’s t test).
Fig. 7. Effect of hrLH on MMP2 secretion by Hec1A cells seeded onto Matrigel. Cells
were seeded in DMEM  BSA onto Matrigel in the absence or in the presence of 0.3
UI/ml hrLH, and then enzymatic activity was detected with zymography. Representative
gelatin zymograms of samples from untreated cells (Lane 1), cells treated with 0.3 UI/ml
hrLH (Lane 2), cells treated with 0.3 UI/ml hrLH in the presence of 10 M PKA-inhibitor
H89 (Lane 3), and from cells treated with hrLH in the presence of 1:40 anti-1 (anti-
FN-R) antibodies (Lane 4). Purified MMP-2 and MMP-9 from a culture of HT1080 were
used as standard reference of both inactive and active forms of the enzymes (23) and were
run in parallel (St).
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avidity for the substratum more than by an increase in the amount of
integrin expression on the plasma membrane.
Hence, the possibility that inhibition of 1 integrins could also interfere
with Hec1A cell invasion through Matrigel was analyzed: as shown in
Fig. 6, the addition of various amounts of anti 1 antibodies to hrLH-
treated Hec1A cells induced a dose-dependent inhibition of cell invasion
through Matrigel (Fig. 6a). On the other hand, anti-3 antibodies did not
affect the hrLH-induced increase in Hec1A cell invasiveness (Fig. 6b).
On the whole, data obtained thus far indicate that EC cell invasion
through Matrigel occurs via the functional activation of 1 adhesiveness
induced by hrLH.
Therefore, the secretion of MMPs was tested on Hec1A seeded onto
Matrigel in the absence or in the presence of hrLH through a zymo-
graphic assay. Fig. 7 shows that Hec1A cells are almost unable to secrete
MMPs in basal conditions (control), as reported previously (8). The
addition of hrLH induces the secretion of active MMP-2 (bottom arrow
on the left side of Fig. 7), a MMP widely involved in tumor cell invasion
through basement membranes (9, 29, 30). Interestingly, the induction of
MMP-2 secretion by hrLH was completely abolished by pretreatment of
cells with the PKA inhibitor H89, here again, stressing the relevance
of this signaling pathway in the proinvasiveness activity of hrLH on EC
cells. Moreover, preincubation with anti-FN-R (anti-1) antibodies abol-
ishes the proteolytic activation of the proenzyme MMP-2, thus leading to
an accumulation of its inactive form.
On the whole, data gathered thus far in the Hec1A cell model indicate
that hrLH (as well as hCG) increases tumor cell invasion through the
basal membrane-mimicking substratum Matrigel by activating the LH/
hCG-R-dependent cAMP/PKA signaling pathway, which in turn
switches on proinvasion mechanisms centered on the activation of 1
integrin avidity for Matrigel substratum and induction of the secretion of
active MMP2.
The possibility that this mechanism could be somehow involved in EC
cell invasiveness in vivo was then studied. As a first approach, we tested
whether the LH/hCG-R was indeed expressed in primary human EC, as
reported by Lin et al. (13). Results obtained from 22 cases of primary EC
indicated that 45% of tumors indeed expressed the receptor (Table 1 and
Fig. 8). It is worth noting (Fig. 8, Lane 4) that EC samples expressed
mainly the splice variant weighing 153 bp as reported by Lin et al. (13).
A cell invasion assay was therefore performed as above on selected
cases from Table 1 displaying different expression of LH/hCG-R, imme-
diately after surgical removal form the uterus. As shown in Fig. 9a, five
of seven cases increased their migratory activity after hrLH addition with
an average doubling of the number of migrated cells after 24 h of
incubation in the presence of the GT. Interestingly, here again, the
hrLH-induced effect was apparently related to the expression of LH/
hCG-R by tumor cells. In fact, only those primary tumors that expressed
the LH/hCG-R increased their invasion through Matrigel in response to
hrLH addition (compare samples in Fig. 9 with those in Table 1).
Interestingly, the proinvasiveness effect of hrLH turned out to be, here
again, almost completely inhibited by the PKA inhibitor H89 (Fig. 9b).
Fig. 8. LH/hCG receptor expression in the human Hec1A cell line and in a represent-
ative primary endometrial adenocarcinoma sample. RNA extracted from human testis (as
positive control), Hec1A and primary EC samples were retrotranscribed and amplified by
a nested PCR using two couple of primers specific for Lh/hCG-R. Lane 1: molecular
weight standard 100 bp (New England Biolabs); Lane 2: testis; Lane 3: Hec1A; Lane 4:
primary EC sample; and Lane 5: omissis template as negative control. The panel at the
bottom shows the amplification of human (gapdh) mRNA as a positive procedural control
as well as for determination of the integrity of RNA.
Table 1 LH/hCG-R expression in primary EC
RNA extracted from tissue samples of different ECs were retrotranscribed and ampli-
fied by a nested PCR using two couple of primers specific for Lh/hCG-R (see “Materials
and Methods”). Amplification of gapdh as a positive internal control as well as for
determination of the integrity of RNA was performed for each sample (data not shown).
Histotype LH-R
AC-SDa 
AC-SD 
S-AC 
E-AC 
E-AC 
AC-SD 
E-AC 
E-AC 
E-AC 
E-AC 
AC-SD 
E-AC 
E-AC 
CC-AC 
E-AC 
AC-SD 
E-AC 
E-AC 
E-AC 
SR-AC 
AC-SD 
E-AC 
a AC-SD, adenocarcinoma endometrioid with squamous differentiation; S-AC, secre-
tory adenocarcinoma; E-AC, endometrioid adenocarcinoma; CC-AC, clear cell adenocar-
cinoma; and SR-AC, serous adenocarcinoma.
Fig. 9. a, effect of hrLH on invasiveness of tumor cells
from primary selected EC samples. The invasion assay was
performed as reported in the legend to Fig. 1 on endometrial
adenocarcinoma cells extracted directly from fresh tissues
belonging to 7 of 22 samples reported in Table 1. Sample
numbers correspond to those reported in Table 1. Bars
represent the percentage of migrated cells in the presence of
0.3 UI/ml hrLH as compared with the untreated controls,
represented in the figure by the continuous line intercepting
the y axis at the value of 100. b, effect of the PKA inhibitor
H89 on the migration of adenocarcinoma cells induced by
hrLH. The invasion experiment was carried out as described
in the legend to Fig. 3 on three adenocarcinoma samples,
two of which correspond to samples reported in a and in
Table 1. Data are reported as the percentage of migrated
cells as compared with untreated cells (control) and are the
means  SE of three separate experiments, each carried out
in triplicate.   significantly different as compared with
“control” (Student’s t test; P  0.002);   significantly
different as compared with “hrLH” (Student’s t test;
P  0.026).
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On the whole, these results indicate that the activation of LH/hCG-R
by the proper ligand induces an increase in cell invasiveness also of
primary EC cells, here again, through the activation of PKA signaling.
In this study, we provide evidence that LH/hCG is involved in tumor
progression of EC because it induces an invasive phenotype in the
moderately differentiated EC cell line Hec1A. The mechanism for this
involves LH/hCG binding to its receptor and inducing the activation of
PKA, which in turn activates 1 integrin adhesiveness to Matrigel and
therefore the secretion of active MMP-2. In this light, PKA has been
indeed recently reported to positively regulate cell spreading and motility
in different cellular models (31, 32); moreover, our data show that the
PKA-dependent activation of 1 integrin appears to be also necessary for
the induction of the enzymatic activation of MMP-2.
Data demonstrating that this mechanism is also operative in pri-
mary EC are presented. No data regarding a direct effect of LH/hCG
on EC cell lines and primary EC invasiveness have been published
previously to the best of our knowledge.
Data reported in this article not only stress the role of GTs as tumor
progression factors but also lend support to the use of GnRH ana-
logues to inhibit pituitary LH secretion in the therapeutic protocols of
LH/hCG-R-expressing tumors (19) because this use could block the
invasive features of the tumor and thus permit longer survival, often
without interfering with other aspects of neoplastic growth such as
proliferation and differentiation as reported by Noci et al. (19).
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